Checkmate.

Bristol-Myers Squibb is throwing in the towel on nivolumab concurrent with upfront radiation for unmethylated glioblastoma multiforme (GBM) with a press announcement that it did not improve overall survival when compared to the standard temozolomide. | BMS 2019